Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, t...

Full description

Bibliographic Details
Main Authors:	Nan Zhang, Xu Yang, Mingjian Piao, Ziyu Xun, Yunchao Wang, Cong Ning, Xinmu Zhang, Longhao Zhang, Yanyu Wang, Shanshan Wang, Jiashuo Chao, Zhenhui Lu, Xiaobo Yang, Hanping Wang, Haitao Zhao
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	Biomarker Research
Subjects:	Hepatocellular carcinoma Programmed death-1 Programmed death ligand 1 Immune checkpoint inhibitors Biomarker
Online Access:	https://doi.org/10.1186/s40364-023-00535-z

Similar Items

PD-L1 and PD-1 in immune regulation and their implications in blood cancers
by: Parisa Shiri Aghbash, et al.
Published: (2024-10-01)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018-04-01)

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer
by: Jee Hyun Ahn, et al.
Published: (2017-12-01)

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
by: Seher Şener, et al.
Published: (2021-10-01)

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
by: Mutiara Indah Sari, et al.
Published: (2022-08-01)

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis
by: Tzu-Rong Peng, et al.
Published: (2023-11-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation
by: Taisuke Kaiho, et al.
Published: (2023-11-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
by: Lin Zhang, et al.
Published: (2022-01-01)

Comparison of Immune Checkpoint Molecules <i>PD-1</i> and <i>PD-L1</i> in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
by: Wei Yu, et al.
Published: (2022-02-01)

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
by: Nishant Thakur, et al.
Published: (2021-03-01)

Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma
by: QIAO Jiahua*, HAO Ziqi, HUANG Ye, WEI Junni, LI Suhong
Published: (2024-02-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
by: Xinfang Yu, et al.
Published: (2021-11-01)

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
by: Xiang Chen, et al.
Published: (2024-02-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
by: Feng YC, et al.
Published: (2018-01-01)

PD-1 immunology in the kidneys: a growing relationship
by: Ruyue Chen, et al.
Published: (2024-10-01)

Research progress on photodynamic therapy combined with PD-1/PD-L1 inhibitors in anti-tumor therapy
by: Yu Xin, Ye Tinglu
Published: (2023-02-01)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023-05-01)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
by: Sandra Schöniger, et al.
Published: (2022-10-01)

Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events
by: YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng
Published: (2022-04-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis
by: Shiya Ji, et al.
Published: (2025-02-01)

Role of B cells in anti-PD-(L)1 therapy in tumor bearing mice
by: HOU Junlei, et al.
Published: (2024-04-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Truncated PD1 Engineered Gas‐Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells
by: Siyan Zhang, et al.
Published: (2024-03-01)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023-01-01)

Clinical and Prognostic Significance of PD-L1, Beclin 1 and Fascin 1 Immunohistochemical Expression in Colorectal Carcinoma
by: Sabah Mohamed Hanafy, et al.
Published: (2023-10-01)

The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma
by: Young Wha Koh, et al.
Published: (2024-08-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
by: Seung Bae Yoon, et al.
Published: (2024-03-01)

PD-1/PD-L1 and DNA Damage Response in Cancer
by: Mateusz Kciuk, et al.
Published: (2023-02-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
by: Meiyan Zhu, et al.
Published: (2024-04-01)